Altered Dimerization of Metabotropic Glutamate Receptor 3 in Schizophrenia

Biological Psychiatry

Volumn 62, Issue 7, 2007, Pages 747-755

  Corti, Corrado ^a,b   Crepaldi, Luca ^c   Mion, Silvia ^a   Roth, Adelheid L ^a   Xuereb, John H ^b   Ferraguti, Francesco ^b,c  

^a GSK   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Brodmann area 10; dimer; mGlu3; prefrontal cortex; schizophrenia; vesicular glutamate transporter

Indexed keywords

METABOTROPIC RECEPTOR 3; VESICULAR GLUTAMATE TRANSPORTER 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIMERIZATION; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALE; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; AUTOPSY; BLOTTING, WESTERN; COHORT STUDIES; DENSITOMETRY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RECEPTORS, METABOTROPIC GLUTAMATE; RECOMBINANT PROTEINS; SCHIZOPHRENIA;

EID: 34547692661     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.12.005     Document Type: Article

References (53)

1. AbdAlla S., Lother H., el Massiery A., and Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7 (2001) 1003-1009
2. Bellocchio E.E., Hu H., Pohorille A., Chan J., Pickel V.M., and Edwards R.H. The localization of the brain-specific inorganic phosphate transporter suggests a specific presynaptic role in glutamatergic transmission. J Neurosci 18 (1998) 8648-8659
3. Bishop J.R., Ellingrod V.L., Moline J., and Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 77 (2005) 253-260
4. Bulenger S., Marullo S., and Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 26 (2005) 131-137
5. Cartmell J., Monn J.A., and Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291 (1999) 161-170
6. Chen Q., He G., Chen Q., Wu S., Xu Y., Feng G., et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 73 (2005) 21-26
7. Ciruela F., Escriche M., Burgueno J., Angulo E., Casado V., Soloviev M.M., et al. Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem 276 (2001) 18345-18351
8. Corti C., Aldegheri L., Somogyi P., and Ferraguti F. Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience 110 (2002) 403-420
9. Crook J.M., Akil M., Law B.C., Hyde T.M., and Kleinman J.E. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 7 (2002) 157-164
10. Eastwood S.L., and Harrison P.J. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: Further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 73 (2005) 159-172
11. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 101 (2004) 12604-12609
12. Ferraguti F., Corti C., Valerio E., Mion S., and Xuereb J. Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5. Exp Brain Res 137 (2001) 1-11
13. Fujii Y., Shibata H., Kikuta R., Makino C., Tani A., Hirata N., et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 13 (2003) 71-76
14. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158 (2001) 1367-1377
15. Gupta D.S., McCullumsmith R.E., Beneyto M., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57 (2005) 123-131
16. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 Pt 4 (1999) 593-624
17. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 10 (2005) 40-68 image 45
18. Homayoun H., Jackson M.E., and Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93 (2005) 1989-2001
19. Hynd M.R., Lewohl J.M., Scott H.L., and Dodd P.R. Biochemical and molecular studies using human autopsy brain tissue. J Neurochem 85 (2003) 543-562
20. Kaneko T., Fujiyama F., and Hioki H. Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain. J Comp Neurol 444 (2002) 39-62
21. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179 (2005) 303-309 (Berl)
22. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
23. Kubo Y., and Tateyama M. Towards a view of functioning dimeric metabotropic receptors. Curr Opin Neurobiol 15 (2005) 289-295
24. Kunishima N., Shimada Y., Tsuji Y., Sato T., Yamamoto M., Kumasaka T., et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407 (2000) 971-977
25. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., and Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 (2001) 455-467
26. Lewis D.A., and Lieberman J.A. Catching up on schizophrenia: Natural history and neurobiology. Neuron 28 (2000) 325-334
27. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., and Varney M.A. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117 (2003) 697-706
28. Markou A. Metabotropic glutamate receptor antagonists: Novel therapeutics for nicotine dependence and depression?. Biol Psychiatry 61 1 (2007) 17-22
29. Marti S.B., Cichon S., Propping P., and Nothen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 114 (2002) 46-50
30. Melendez R.I., Gregory M.L., Bardo M.T., and Kalivas P.W. Impoverished rearing environment alters metabotropic glutamate receptor expression and function in the prefrontal cortex. Neuropsychopharmacology 29 (2004) 1980-1987
31. Milligan G. G protein-coupled receptor dimerization: Function and ligand pharmacology. Mol Pharmacol 66 (2004) 1-7
32. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
33. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281 (1998) 1349-1352
34. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20 (1999) 106-118
35. Norton N., Williams H.J., Dwyer S., Ivanov D., Preece A.C., Gerrish A., et al. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 5 (2005) 23
36. Ohishi H., Shigemoto R., Nakanishi S., and Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study. J Comp Neurol 335 (1993) 252-266
37. Ohnuma T., Augood S.J., Arai H., McKenna P.J., and Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 56 (1998) 207-217
38. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52 (1995) 998-1007
39. Petralia R.S., Wang Y.X., Niedzielski A.S., and Wenthold R.J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71 (1996) 949-976
40. Richardson-Burns S.M., Haroutunian V., Davis K.L., Watson S.J., and Meador-Woodruff J.H. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 47 (2000) 22-28
41. Romano C., Miller J.K., Hyrc K., Dikranian S., Mennerick S., Takeuchi Y., et al. Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization. Mol Pharmacol 59 (2001) 46-53
42. Sartorius L.J., Nagappan G., Lipska B.K., Lu B., Sei Y., Ren-Patterson R., et al. Alternative splicing of human metabotropic glutamate receptor 3. J Neurochem 96 (2006) 1139-1148
43. Schoepp D.D., Jane D.E., and Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 (1999) 1431-1476
44. Tabata T., Araishi K., Hashimoto K., Hashimotodani Y., van der Putten H., Bettler B., et al. Ca2+ activity at GABAB receptors constitutively promotes metabotropic glutamate signaling in the absence of GABA. Proc Natl Acad Sci U S A 101 (2004) 16952-16957
45. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J., et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113 (2004) 1353-1363
46. Tamaru Y., Nomura S., Mizuno N., and Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites. Neuroscience 106 (2001) 481-503
47. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12 (1998) 21-36
48. Tascedda F., Blom J.M., Brunello N., Zolin K., Gennarelli M., Colzi A., et al. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50 (2001) 117-122
49. Tateyama M., Abe H., Nakata H., Saito O., and Kubo Y. Ligand-induced rearrangement of the dimeric metabotropic glutamate receptor 1alpha. Nat Struct Mol Biol 11 (2004) 637-642
50. Terrillon S., and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 5 (2004) 30-34
51. Thaker G.K., and Carpenter Jr. W.T. Advances in schizophrenia. Nat Med 7 (2001) 667-671
52. Tsuji Y., Shimada Y., Takeshita T., Kajimura N., Nomura S., Sekiyama N., et al. Cryptic dimer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1. J Biol Chem 275 (2000) 28144-28151
53. Xi Z.X., Ramamoorthy S., Baker D.A., Shen H., Samuvel D.J., and Kalivas P.W. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther 303 (2002) 608-615